Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
With
University of Chicago
Mayo Clinic
Vanderbilt University
This study will use the Clinical Impact Method to develop a patient reported outcome for use in patients with pulmonary arterial hypertension Clinical personnel at the study sites will approach and discuss possible participation in Phase I and II of the study with subjects from the existing pool of patients currently receiving usual and customary care at the site.
Age
18–100
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Evidence of a personally signed and dated informed consent
Subjects aged \>=18 who have documented PAH
Speak English
Subjects who provide written informed consent to participate in the study before being screened for the study.
You may not be if
Patients with non-PAH Pulmonary Hypertension
Physical inability to complete the interview process
Subjects who are currently enrolled in an experimental drug study
Clareo Health | Patient Reported Outcomes in Pulmonary Arterial Hypertension
